Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.

The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034, according to a Jan. 31 news release from ResearchandMarkets.com.

Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.

Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal's Agili-C implant in Washington state, according to a Jan. 27 LinkedIn post. 

Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer, according to a Jan. 27 news release. 

LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.

SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.

Royal Biologics and Fair Winds Medical partnered to distribute spine and orthopedic biologics, according to a Jan. 16 news release.

From new studies and milestones, here are seven key updates in orthobiologics since Nov. 13.

Ventris Medical earned FDA 510(k) clearance for its Backpack bone graft containment system, according to a Jan. 9 news release. 

Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology. 

Orthobiologics piqued the interest of spine surgeons and Becker's readers in 2024. Here are four key conversations.

Durham, N.C.-based Duke University has won a $3.9 million grant to study gender differences in ACL injuries, according to a Dec. 20 report from WRAL News.

Columbus, Ohio-based Atreon Orthopedics has completed 10,000 rotator cuff repair surgeries with the use of its Rotium bioresorbable wick. 

RTI Surgical, a contract development and manufacturing organization for regenerative medicine, rebranded to Evergen.

A clinical trial out of the University of California San Diego School of Medicine found that neural stem cell transplantation had shown long-term safety and feasibility for treating chronic spinal cord injuries.

Theradaptive earned the FDA's investigational device exemption approval to broaden its clinical research for the OsteoAdapt SP implant, the company said Dec. 10.

Three-year data for the Discseel spine procedure found it was effective and could replace most spine surgeries, Discseel Technologies said Dec. 4. 

Bioretec signed a distribution agreement to accelerate commercialization of the RemeOs trauma screw system in the U.S., according to a Nov. 22 news release. 

From company acquisitions to FDA nods, here are six key updates in orthobiologics since Oct. 4.